Articles From Our Expert Network
-
Capacity & Competency Of The Clinical Research Workforce — Today & Tomorrow
9/29/2020
It’s not simply an issue of supply and demand. It’s closer to life and death. Put bluntly, we may not be able to keep up with future clinical trial demand because our workforce isn’t growing fast enough. In fact, by some metrics, we’re already falling behind.
-
COVID-19’s Impact On The Clinical Trial Ancillary Supplies Industry
9/24/2020
With restrictions on logistics, and countries implementing new restrictions to address increasing COVID-19 cases, it’s important to understand how to manage clinical trials’ ancillary supplies — like sourcing from the right suppliers, managing distribution to all trial sites, stock management, and response to new regulations.
-
Safeguarding Participant Data During Risk-based Monitoring — Practical Considerations
9/22/2020
With risk-based monitoring becoming more common, and with sponsor/CRO monitors reviewing electronic source data remotely, many questions have arisen regarding what security measures need to be in place to ensure the protection of study participants’ data.
-
How Storyboarding Can Bring Clarity To Regulatory Inspection Readiness & Facilitation
8/25/2020
Developing storyboards for regulatory inspection readiness and facilitation is a growing trend, yet the tool is shrouded in mystery for many pharma industry professionals. (Downloadable storyboard template included.)
-
Discovering & Motivating Talent In The Life Sciences: Redefining “Other Duties & Responsibilities”
8/21/2020
How do we attract the right kind of talent to a role within our organizations? How do we take the same innovative approaches in our talent acquisition processes that we put into our products? One answer can be found in an often-overlooked bullet point in a common job description: “other duties and responsibilities as required.”
-
Transformative Reflections On The Life Science World, Post-COVID-19
7/23/2020
The post-pandemic response has led to drastic public health changes and new ways of creating diagnostics and treatments. COVID-19 was a turning point. The pandemic exposed weaknesses in internal processes, reliance upon traditional methodologies, and leadership gaps. It demonstrated a valuable capacity to leverage innovative technologies for prioritizing patient safety, to rapidly implement creative ways of enabling healthcare providers to continue providing care, and a new framework for solving complex medical challenges.
-
Remote Monitoring In The Wake Of COVID-19 — Practical & Regulatory Considerations
6/30/2020
In the long term, as we move into the reopening phases of COVID-19, faced with increased expenses and the challenges with on-site monitoring, clinical research professionals need to ensure their quality management systems have the flexibility for the new normal for site management.
-
The Expanding Role Of Artificial Intelligence In Clinical Research
6/9/2020
While protocols and standards in clinical research have become increasingly complex, slowing progress and increasing costs, companies from startups to Big Pharma are identifying opportunities to apply AI to enhance trial efficiency, patient enrollment, and outcomes targeting.
-
Rethinking Recruitment Plans During The Pandemic
4/7/2020
Once the care and management of current clinical trial participants have stabilized, we can find some silver linings in the pause. Sponsors and CROs can use this opportunity to rethink their recruitment plans, support site sustainability, and intelligently prepare for the ultimate ramp up of trial enrollment.
-
Clinical Study Risk Management During The COVID-19 Pandemic
4/6/2020
While COVID-19 has proven to be an extremely trying obstacle for the life science community, it is crucial for organizations to not only focus on the short-term impacts of COVID-19 but on developing a long-term plan of action for how we return to business once the pandemic subsides.